A recent study published in JAMA Network Open has shown promising results regarding the safety of receiving mRNA COVID-19 and inactivated influenza vaccines simultaneously. The randomized control trial, conducted from October 2021 to June 2023 at three U.S. study sites, included 335 participants aged 5 years and older. The participants were divided into two groups, with one group receiving the vaccines simultaneously and the other receiving them sequentially, 1 or 2 weeks apart.
The study focused on assessing reactogenicity, including symptoms such as fever, chills, muscle aches, and joint pain of moderate or greater severity within seven days after vaccination. The results indicated that participants who received the vaccines simultaneously had no more adverse effects than those who received them sequentially. In both groups, fewer than 13% of participants experienced severe reactions, and no participants required medical attention for any solicited reactions.
Furthermore, there was no significant difference in health-related quality of life indexes between the two groups. The authors of the study concluded that simultaneous administration of mRNA COVID-19 and influenza vaccines is a viable strategy to achieve high vaccination coverage during periods of increased transmission of both viruses.
The study also revealed that more than half of the participants had a history of SARS-CoV-2 infection or detectable antibodies to the virus at the time of enrollment. This information provides valuable insight into the potential benefits of concurrent vaccination against COVID-19 and influenza.
Overall, the findings of this trial support the safety and feasibility of administering mRNA COVID-19 and inactivated influenza vaccines simultaneously. This approach may help streamline vaccination efforts and improve overall vaccination coverage during times of heightened virus transmission. Further research and monitoring will be essential to confirm these results and guide future vaccination strategies.
